All In Biotech

Drug Trial Radar · NCT03644264

PA21 Safety and Efficacy in Adult Chinese Subjects

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela®) in Chinese CKD Patients With Hyperphosphataemia

Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

286

Actual

Start

Aug 31, 2018

Primary completion

Aug 21, 2020

Study completion Aug 21, 2020

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.

Conditions

  • Chronic Kidney Disease Requiring Chronic Dialysis
  • Hyperphosphatemia

Interventions

  • PA21Drug

    sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.

  • sevelamer carbonateDrug

    sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum phosphorus (mmol/l )Time frame: baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Southern Medical University Nanfang Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.